Does continuous intravenous epoprostenol improve symptoms, hemodynamics, and survival in patients with severe primary pulmonary hypertension?
Continuous intravenous epoprostenol improves survival, symptoms, and hemodynamics in patients with severe primary pulmonary hypertension compared to conventional therapy.
As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
Barst et al. (1996) studied this question.